As coronary CT angiography (CCTA) continues its rapid expansion, scanner vendors are now offering more economical solutions to ensure access to imaging technology beyond premium systems most often only found at flagship hospitals and academic centers. To conquer CCTA’s technical challenges, new technologies and AI are being incorporated into a new scanner to simplify acquisition and consistently improve image quality. 

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.

Caristo Diagnostics, an Oxford-based medtech company founded by cardiologists, has gained FDA clearance for its CaRi-Plaque technology.

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

SCAI President James Hermiller, Jr., MD, explains the need for more innovative radiation protection systems in the cath lab.

CCTA continues to grow more and more important in the day-to-day treatment of heart patients. Hospitals and health systems that fail to embrace the modality risk falling behind.

Evan Shlofmitz, DO, director of intravascular imaging at St. Francis Hospital, explains how advanced artificial intelligence technology is used to assess a patient's CT scan before they undergo PCI.